Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: a 6 Months Prospective Study
Background: Some patients experience statin-induced side effects or prefer nutraceutical approaches for the treatment of dyslipidemia. This has led to a search for alternative therapeutic approaches for dyslipidemia management. In recent studies Citrus bergamia (known as Bergamot) juice was able to...
Main Authors: | Peter P. eToth, Angelo Maria ePatti, Dragana eNikolic, Rosaria Vincenza eGiglio, Giuseppa eCastellino, Teresa eBiancucci, Fabiana eGeraci, Sabrina eDavid, Giuseppe eMontalto, Ali eRizvi, Manfredi eRizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00299/full |
Similar Items
-
Mouse models in Arrhythmogenic Right Ventricular Cardiomyopathy
by: Elisabeth M Lodder, et al.
Published: (2012-06-01) -
Hippocampal hyperexcitability is modulated by microtubule-active agent: evidence from in vivo and in vitro epilepsy models in the rat.
by: Fabio eCarletti, et al.
Published: (2016-02-01) -
Addressing the complexity of Tourette’s syndrome through the use of animal models.
by: Ester eNespoli, et al.
Published: (2016-04-01) -
Dissecting mechanisms of brain aging by studying the intrinsic excitability of neurons
by: Valerio eRizzo, et al.
Published: (2015-01-01) -
HLA-G molecules in autoimmune diseases and infections
by: Roberta eRizzo, et al.
Published: (2014-11-01)